Skip to main content
PLOS One logoLink to PLOS One
. 2026 Nov 6;21(11):e0361954. doi: 10.1371/journal.pone.0361954

Evaluation of the efficacy of Si-based agent in Rheumatoid Arthritis with complicating vestibular impairment

Shotaro Harada 1,2,#, Yoshihisa Koyama 1,3,*,#, Yuki Kobayashi 4, Takao Imai 2, Yoshichika Yoshioka 5,6, Hikaru Kobayashi 4, Hidenori Inohara 2, Shoichi Shimada 1,3
Editor: Toru Miwa7
PMCID: PMC13742939  PMID: 42993734

Abstract

Background

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and progressive disability. Although current therapies have improved clinical outcomes, safer and more effective therapeutic approaches remain needed. Silicon (Si)-based agents have antioxidant and anti-inflammatory properties and have shown beneficial effects in several inflammatory disease models.

Methods

We evaluated the effects of oral administration of a Si-based agent in a type II collagen-induced arthritis mouse model. Arthritis severity was assessed using an arthritis index, hindlimb oedema, and the hindlimb extension reflex test. Serum type II collagen-specific autoantibody levels were also measured. Vestibular function was evaluated using the vestibulo-ocular reflex (VOR), and inner-ear structural changes were assessed by magnetic resonance imaging and histological analysis.

Results

The Si-based agent reduced arthritis-related outcomes, including the arthritis index, hindlimb oedema, and joint movement restriction, and reduced serum type II collagen-specific autoantibody levels. In contrast, no significant differences between the Si-based agent and control groups were detected in VOR-related outcomes, endolymphatic space measurements, or inner-ear histological findings.

Conclusions

These findings suggest that the Si-based agent may have beneficial effects on arthritis-related manifestations. However, its effects on the vestibular function-related outcomes examined in this study were not evident. Further studies are needed to clarify the relationship between RA and vestibular dysfunction and to determine the potential therapeutic effects of Si-based agent on these complications.

Introduction

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent synovial inflammation, leading to progressive joint destruction, pain, and disability. It affects approximately 1% of the adult population worldwide and is frequently associated with extra-articular manifestations involving the cardiovascular, pulmonary, ocular, and nervous systems [1]. Persistent systemic inflammation, driven by pro-inflammatory cytokines such as TNF-α, IL-1, and IL-6, may also contribute to dysfunction in sensory systems, including the auditory and vestibular organs. Several studies have reported vestibular dysfunction in patients with RA [2,3]. Reportedly, it was suggested that increased latency and amplitude asymmetry ratios in vestibular evoked myogenic potential responses were associated with impaired balance control and increased fall risk [4]. Importantly, such dysfunction may contribute to balance impairment, dizziness, and falls, thereby reducing patients’ quality of life. Although disease-modifying antirheumatic drugs (DMARDs) and biologic agents have improved the management of joint inflammation and systemic symptoms, vestibular complications remain insufficiently addressed [1]. Therefore, the development of therapeutic strategies that target not only joint destruction, but also neurological and sensory manifestations is urgently needed to achieve comprehensive disease control and improve outcomes for patients with RA.

Silicon (Si)-based agent react with water to continuously generate large amounts of hydrogen [5]. Hydrogen has anti-inflammatory and antioxidant effects and has been shown to be effective on sensory cells in the inner ear [6]. Previous reports have shown that oral administration of Si-based agent can alleviate the symptoms of various inflammatory diseases, including ulcerative colitis and interstitial pneumonia [7,8]. Therefore, it is expected that Si-based agent, which are effective in treating disorders of various organs throughout the body, may potentially be effective for RA, including vestibular dysfunction.

In our previous study, we demonstrated that mice with type II collagen-induced RA caused vestibular dysfunction. Since type II collagen is abundant in the inner ear tissue, it has been suggested that the autoimmune system reacts to this type II collagen, destroying vestibular hair cells and resulting in a decline in vestibular function [9]. In this study, we used a mouse model with type II collagen-induced RA to examine whether Si-based agent could be effective in treating RA and vestibular dysfunction.

Materials & Methods

Ethics statement

All experiments involving mice were performed in accordance with protocols approved by the Committee of Animal Experiments of Osaka University (Approval No. 02-001-015) and adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. This study complied with the ARRIVE guidelines. Efforts were made to minimize the number of animals used and to reduce animal suffering. Animals showing signs of distress or reaching predefined humane endpoints were euthanized by intraperitoneal administration of pentobarbital (200 mg/kg).

Animals and model preparation

The experiments were conducted using 7-week-old male DBA/1J mice (Japan SLC, Shizuoka, Japan). The mice were provided with rodent diet and water ad libitum, maintained at a consistent temperature of 23–25°C. The Si-based agent was prepared using the bead-milling method according to a previous report [10], mixed with AIN93M (Oriental Yeast Co., Ltd., Tokyo, Japan) at a concentration of 2.5%, and administered to mice. The group treated with the Si-based agent was designated as the Si group, and the group administered AIN93M (Oriental Yeast Co., Ltd.) was designated as the Con group. The mice were randomly divided into two groups (n = 9 per group). For reference in the measurement of serum type II collagen-specific autoantibodies, seven untreated normal 19-week-old DBA/1J mice were also prepared.

The RA mouse models were prepared by Japan SLC using an established protocol based on previous reports [9]. The RA model was established as follows: Equal volumes of an antigen solution (0.01 M acetate phosphate buffer containing 8 mg/mL bovine type II collagen) and an adjuvant solution (a mixture containing dead Mycobacterium tuberculosis H37Ra and 4 mg/mL Freund’s incomplete adjuvant) were placed in separate luer lock glass syringes. The antigen solution was then transferred to a syringe containing the adjuvant solution. The contents were alternately pushed between syringes and mixed to form an emulsion. The collagen solution was intradermally administered twice under isoflurane inhalation anaesthesia. The first sensitisation was performed intradermally at the base of the auricle at 8 weeks of age and the second was administered intradermally at the base of the tail three weeks later. For both administrations, the dosage was 0.025 mL per animal, equivalent to a total of 0.2 mg of collagen per animal.

The mice were assessed using an arthritis index based on a 4-point scale: 0 (no change), 1 (toe swelling), 2 (swelling of the toes and soles), 3 (swelling of the entire foot), 4 (severe swelling), and 5 (bone degeneration). If bone degeneration was observed, an additional point (+1) was assigned. A score of 1 or higher was considered indicative of arthritis [11]. A single evaluator, who was independent of the personnel responsible for arthritis induction and treatment, performed the arthritis scoring. The evaluator was unaware of the group assignments and individual treatment information at the time of assessment. The hind limb oedema rate was determined using the following formula:

The~hindlimb~oedema~rate~(\%)=~(Hindlimb~volume~after~treatment−~Hindlimb~volume~before~treatment)Hindlimbvolumebeforetreatment×100

Moreover, to examine joint pain and degeneration associated with inflammation, the muscle-nerve reflex was evaluated in the open-leg position using the hind limb extension reflex test [12].

Vestibulo-ocular reflex test

Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), and local anesthesia (1% lidocaine) was applied to the scalp. A Z-shaped metal fitting was secured to the skull using dental cement to immobilize the head during recording. Experiments were performed 24 h after attachment of the fitting [13].

Based on our previous findings [9], VOR was selected because it detected differences between normal mice and RA mouse models, whereas static tilt did not. VOR was induced by horizontal sinusoidal rotation in darkness at 0.3, 1, and 2 Hz using an automatically controlled turntable [14]. Eye movements were recorded with a high-speed infrared camera at 240 Hz and synchronized with turntable movement using StreamPix software. For each frequency, 7–14 recordings were obtained, and 3–5 recordings with adequate image quality were selected for analysis.

Eye movement analysis

Eye movements were analyzed from 645 × 485-pixel images using a previously described method [13,15]. The three-dimensional position of the pupil center was reconstructed from the two-dimensional pupil ellipse and the estimated center of eyeball rotation. Horizontal eye rotation was then calculated from the reconstructed pupil coordinates. The angular position of the turntable was determined from two markers using the atan2 function [13], and angular velocities of the turntable and eye movements were calculated by differentiating their respective angular positions.

VOR gain calculation

Turntable and eye angular velocities were fitted to sinusoidal functions by least-squares regression. VOR gain was calculated as the ratio of peak eye velocity to peak turntable velocity [16–18].

Tissue sample preparation and Hematoxylin-Eosin stain

Mice were fixed by perfusion using 4% paraformaldehyde (PFA) fixative under anaesthesia with a combination of anesthetic (0.3 mg/kg medetomidine, 4.0 mg/kg midazolam, and 5.0 mg/kg butorphanol) [19]. Temporal bones, including the cochlea and semicircular canal, were quickly removed under a microscope (Leica, Wetzlar, Germany) and replaced with cold phosphate-buffered saline (PBS, pH 7.4). The extracted temporal bone was immersed in a 4% PFA fixative at 4°C overnight and then immersed in 10% EDTA in PBS for a week at 4°C for decalcification. The vestibular ganglia were removed after perfusion and postfixed using the same fixative. The samples were dehydrated using a series of ascending alcohol concentrations and embedded in paraffin (tissue preparation, T580, FALMA, Tokyo, Japan) using Clear Plus (FALMA). Sections of 5 μm thickness were prepared with a Rotary microtome (Leika) and mounted on MAS-coated glass slides (Matsunami-glass, Osaka, Japan). The samples were stored at 4°C until further use. After deparaffinisation, the samples were further de-paraffinised with xylene, hydrated through a series of descending alcohol concentrations, and stained with HE solution (FUJIFILM Wako Chemicals Corporation, Osaka, Japan). All stained samples were analysed using a Keyence microscope (KEYENCE Corporation, Osaka, Japan).

Magnetic resonance imaging (MRI)

A Gd MRI contrast agent (0.5 M gadoteridol) was administered intraperitoneally at a dose of 0.10 mL per 20 g of body weight to distinguish the scala vestibuli, scala tympani, and scala media [20]. Sagittal cochlear magnetic resonance images were acquired at 90 min (right side) or 120 min (left side) after Gd administration. In vivo MRI of the mice was performed using an 11.7 T vertical bore scanner (AVANCE II 500WB; Bruker BioSpin, Ettlingen, Germany). Anaesthesia was induced using 2.0% isoflurane and maintained using 1.6% isoflurane during the MRI procedure. Mouse body temperatures were kept at 37°C using circulating warm water. T1-weighted 10 sagittal images of both cochleae were obtained using Rapid Acquisition with Relaxation Enhancement technique [21]. The imaging parameters were as follows: field of view (FOV) = 20 × 20 mm, matrix size = 512 × 512, in-plane resolution = 39 μm, slice thickness = 200 μm, repetition time (TR) = 800 ms, echo time (TE) = 14.8 ms, echo train length = 4, number of averages (NA) = 16, and acquisition time (TA) for each cochlea = 27 min.

Evaluation of the endolymphatic space using inner ear MRI

The endolymphatic space was evaluated using the method described by Imai et al [22]. Briefly, inner ear MRI images at the level of the maximum cochlear axis were magnified 15-fold, and the boundaries of the endolymphatic and perilymphatic spaces were delineated.

The numbers of pixels within each delineated area was calculated, and the area ratio of the endolymphatic space to the perilymphatic space was determined. The area ratio was compared between the Con and Si groups.

Measurement of serum type II collagen autoantibodies

Blood samples were collected from normal mice and mice from the other four groups under deep anesthesia induced with a three-drug anesthetic mixture. Serum was separated by centrifugation (3,000 rpm, 10 min, 4°C) and stored at −80°C. Type II collagen-specific autoantibodies were measured using a type II collagen antibody detection kit (Collagen Research Center, Tokyo, Japan), according to a previous report [9] and the manufacturer’s instructions. Absorbance was measured at 450 nm.

For quantitative analysis, the mean optical density (OD) of the normal mice was set to 1.0, and values for the other four groups were expressed relative to the normal mice.

Statistical analysis

Data are presented as the mean ± SEM unless otherwise indicated. Statistical analyses were performed using Statcel 4 (Excel statistical software) and JMP® Student Edition 19.1.3. For the arthritis index and hindlimb oedema rate, linear mixed-effects model analyses were performed, with treatment group and week as fixed effects and individual mice as a random effect. When a significant treatment group × week interaction was detected, subsequent between-group comparisons at each time point were performed using Student’s t-test, with adjustment for multiple comparisons. Bone degeneration, arthritis severity (arthritis index ≥4), and leg closure rate were compared between groups using Fisher’s exact test. The duration of severe arthritis, defined as the number of weeks during which the arthritis index was ≥ 4, was compared between groups using the Wilcoxon rank-sum test. VOR data were analysed using a two-way mixed-effects model, with treatment group and stimulation frequency as fixed effects and individual animals as a random effect. The endolymphatic space area ratio measured by MRI was analysed using the Mann–Whitney U test, and serum type II collagen-specific autoantibody levels were analysed using one-way analysis of variance (ANOVA) followed by Tukey’s multiple-comparison test. A p-value of < 0.05 was considered statistically significant.

Results

Si-based agent showed efficacy against type II collagen-induced arthritis

First, we investigated whether an Si-based agent is effective against the symptoms of arthritis in a collagen-induced RA mouse model. Arthritis severity was assessed weekly for eight weeks after the second sensitisation using the arthritis index. In the untreated (Con) group, the arthritis index gradually increased from the 1st week, peaked at the 6th week, and then decreased slightly at the 8th week (Fig 1a). However, the arthritis index in the Si-based agent-treated (Si) group showed a similar pattern to that in the Con group, although it remained lower in the Si group from weeks 3–8. A linear mixed-effects model revealed a significant effect of week (p < 0.0001) and a significant treatment group × week interaction (p = 0.0207), whereas the main effect of treatment group was not significant (p = 0.2476).

Fig 1. Analysis of the inflammation in type Ⅱ collagen-sensitized RA mouse models.

Fig 1

(a) Line graph of the average arthritis index in the Con (white) and Si groups (black). X-axis notation: −3 (3 weeks before 2nd sensitisation), 0 (on the day of 2nd sensitisation) and 1–8 (1–8 weeks after the second sensitisation). Data are expressed as the mean ± SEM; n = 9 mice per group. Data were analysed using a linear mixed-effects model, with treatment group and week as fixed effects and individual mice as a random effect. A significant main effect of week (p < 0.0001) and a significant treatment group × week interaction (p = 0.0207) were detected, whereas the main effect of treatment group was not significant (p = 0.2476). Based on significant interaction, post hoc between-group comparisons were performed with adjustment for multiple comparisons. A significant difference between the groups was detected only at week 6 (adjusted p = 0.028). (b) Bar graph showing the proportion of mice with an arthritis index of 4 or higher in the Con (white: 77.8%) and Si (black: 55.6%) group (n = 9 mice per group). No statistically significant difference was detected between the groups (Fisher’s exact test, p = 0.6199). (c) Bar graph showing the proportion of mice with bone degeneration (arthritis index = 5) in Con (white: 77.8%) or Si (black: 11.1%) group (n = 9 mice per group). The incidence of bone degeneration was significantly lower in the Si group than in the Con group (Fisher’s exact test, p = 0.0152). (d) Bar graph showing the mean duration (in weeks) for which the arthritis index was 4 or higher in the control (white) or Si group (black). Data are expressed as the mean ± SEM; n = 9 mice per group. The duration was compared between groups using the Wilcoxon rank-sum test (p = 0.0753). (e) Bar graph of the number of mice per week that arthritis index of 4 or higher persisted in Con (white) or Si group (black). (f) Line graph of the average hindlimb oedema rate. X-axis notation: −3 (3 weeks before 2nd sensitisation), 0 (on the day of 2nd sensitisation) and 1–8 (1–8 weeks after the second sensitisation). Data are expressed as the mean ± SEM; n = 9 mice per group. Data were analysed using a linear mixed-effects model, with treatment group, week, and limb as fixed effects and individual mouse as a random effect. A significant main effect of week was detected (p < 0.0001), whereas no significant main effect of treatment group (p = 0.5494) or group × week interaction (p = 0.1952) was observed.

Post hoc between-group comparisons with adjustment for multiple comparisons revealed a significant difference only at week 6 (adjusted p = 0.028). Additionally, the analysis of the severity of arthritis (score of 4 or more in one of the four limbs) showed that the proportion of mice with severe arthritis in the RA mouse model was lower in the Si group than in the control group (Fig 1b, Con:77.8%, Si:55.6%), although the difference was not statistically significant (Fisher’s exact test, p = 0.6199). Bone degeneration can occur as arthritis becomes more severe [23]. When the incidence of bone degeneration was analysed, 7 of 9 mice (77.8%) in the Con group and 1 of 9 mice (11.1%) in the Si group showed bone degeneration, indicating a significantly lower incidence in the Si group (Fig 1c; Fisher’s exact test, p = 0.0152). Moreover, inflammation persisted for approximately four weeks in the Con group and for approximately two weeks in the Si group (Fig 1d). The duration of severe arthritis, defined as the number of weeks during which the arthritis index was ≥ 4, was numerically shorter in the Si group than in the Con group; however, the difference was not statistically significant (Wilcoxon rank-sum test, p = 0.0753). Particularly, inflammation persisted for more than five weeks in most of the Con group, whereas no mice in the Si group had an arthritis index ≥4 for more than five weeks (Fig 1e). Furthermore, a comparative analysis was conducted on the rate of change in limb volume of oedema associated with inflammation. Oedema was observed in both groups from the 1st week, gradually increasing and peaking at the 5th week. Thereafter, the oedema rate decreased (Fig 1f). The oedema rate in the Si group was lower than that in the Con group at weeks 6 and 7, although no significant difference in the time course of oedema was detected between the groups by linear mixed-effects model analysis.

Moreover, arthritis-related leg closure was assessed using the tail suspension test in mice maintained for an extended period after arthritis onset. When normal mice are suspended in the tail, they instinctively spread their legs owing to neuromuscular reflexes. Spreading the legs maintains the body position and reduces the burden on the tail by redistributing the body weight. In the Con group, most mice were unable to spread their legs when suspended by the tail because of joint pain, and their legs remained rigidly attached to the body (Fig 2a). Conversely, most mice in the Si group opened their legs as soon as their tails were suspended, and actively moved their legs. The percentage of mice that could not open their legs due to joint pain was 77.8% in the Con group and 22.2% in the Si group, indicating that arthritis-related closed legs were alleviated in the Si group (Fig 2b). Although this proportion was lower in the Si group, the difference between groups did not reach statistical significance (Fisher’s exact test, p = 0.0567).

Fig 2. Analysis for the symptoms in type Ⅱ collagen-sensitized RA mouse models.

Fig 2

(a) Representative images of the tail suspension test in the Con (upper line) and Si groups (bottom line). (b) The bar graph indicates the percentage of mice that could not spread their legs in the control (white, 77.8%) and Si groups (black, 22.2%). n = 9 mice per group. The difference between groups was not statistically significant (Fisher’s exact test, p = 0.0567).

Taken together, these findings suggest that Si-based agent may alleviate joint pain by reducing the inflammation associated with arthritis.

No significant differences in VOR gain between the Con and Si groups

Next, VOR analysis was performed to examine whether the Si-based agent affected VOR-related vestibular function in RA mouse models. Lateral semicircular canal function was evaluated using the VOR gain when three stimulation patterns (0.3, 1.0, and 2.0 Hz) were applied. The VOR gain in the Con group was 0.60 ± 0.038 at 0.3 Hz, 0.61 ± 0.039 at 1.0 Hz, and 0.61 ± 0.045 at 2.0 Hz (Fig 3). The VOR gain in the Si group was 0.63 ± 0.034 at 0.3 Hz, 0.60 ± 0.019 at 1.0 Hz, and 0.64 ± 0.058 at 2.0 Hz (Fig 3).

Fig 3. VOR analysis results for RA mouse models.

Fig 3

(a) Overview of VOR equipment. Arrowhead: Mouse fixture. High-speed (240 Hz) infrared camera for capturing the movement of the mouse’s left eyeball (black arrowhead) and movement of the rotating device (black arrow). (b) Line graph of the mean VOR in the Con (white circle) and Si groups (black circle) when stimulated at 0.3, 1, and 2 Hz. Data are expressed as the mean ± SEM; n = 9 mice per group. Data were analyzed using a two-way mixed-effects model, with treatment group and stimulation frequency as fixed effects and individual animals as a random effect. No significant main effect of treatment group (p = 0.4927), stimulation frequency (p = 0.9325), or group × frequency interaction (p = 0.8629) was detected.

A two-way mixed-effects model, with treatment group and stimulation frequency as fixed effects and individual animals as a random effect, showed no significant main effect of treatment group (p = 0.4927) or stimulation frequency (p = 0.9325). No significant group × frequency interaction was detected (p = 0.8629).

Taken together, no significant differences in VOR gain between the Si and Con groups was detected across the stimulation frequencies examined.

No significant differences in inner ear histological findings between the Con and Si groups

Subsequently, to determine whether the Si-based agent could alleviate the structural abnormalities in the inner ear structure in the RA mouse model, the structures of the crista ampullaris of the semicircular canal, otolith organs (utricle and saccule), and vestibular ganglion were evaluated using HE staining. Vacuolisation of the hair cell cytoplasm and loss of the cell nucleus were observed in the crista ampullaris of the semicircular canals and otolith organs in both groups. However, there was no significant difference in the degree of structural collapse between the two groups (Fig 4). In the vestibular ganglion, some areas of the ganglion cells were lost in both groups; however, no significant differences were observed between the two groups (Fig 4f).

Fig 4. Pathological analysis using HE-stained samples.

Fig 4

(a-f) Representative examples of HE-stained images of the lateral semicircular canal (a), the anterior semicircular canal (b), the posterior semicircular canal (c), the utricle (d), the saccule (e) and the vestibular ganglion (f) in the Con (upper images; nine mice) and the Si group (bottom lines; nine mice). Cellular vacuolisation (arrows) and destructed hair cells (arrows). (f) No degenerated and atrophied vestibular ganglion cells of both groups. LSCC: lateral semicircular canal. ASCC: anterior semicircular canal. PSCC: posterior semicircular canal. VG; vestibular ganglion. Scale bar: 20 µm.

Taken together, no significant differences in the histological findings of the inner ear were detected between the Con and Si groups.

No significant difference in the endolymphatic space area ratio between groups

Our previous study revealed that the stria vascularis and spiral ligament were structurally disrupted in RA model mice [9]. These areas are closely involved in endolymph homeostasis. We therefore examined whether long-term administration of the Si-based agent was associated with changes in the endolymphatic space in RA mouse models. To assess the endolymphatic space, MRI analysis of the inner ear was performed in the Si and Con groups.

The image of the area where the modiolus was at its maximum was enlarged by 1500% (Fig 5a and 5b). The area ratio of the endolymphatic space (within the red frame) to the perilymphatic space (within the yellow frame) was calculated and compared between the Si and control groups. The area ratios were 48.6% (SEM ± 2.1%) in the Con group and 52.7% (SEM ± 2.0%) in the Si group (Fig 5c). No significant difference was observed between the two groups (p = 0.1138).

Fig 5. Evaluation of endolymphatic space using MRI analysis.

Fig 5

(a, b) Representative examples of MRI images in the Con (a) and the Si group (b). The left photo is the actual size, and the right photo is a 15× image of orange circle for evaluation. Yellow and red circles indicate the perilymphatic and endolymphatic space, respectively. (c) Bar graph showing the ratio of the endolymphatic/perilymphatic space. To evaluate endolymphatic space, the ratio (%) of the endolymphatic/perilymphatic space pixel count was calculated. Data are expressed as the mean ± SEM of nine mice per group. None: no significance.

Taken together, no statistically significant difference in the endolymphatic space area ratio was detected between the Si and Con groups.

Si-based agent attenuated the dramatic increase in type II collagen autoantibodies associated with RA

Finally, we examined whether the Si-based agent affected blood levels of type II collagen autoantibodies. ELISA showed that 8 weeks after sensitisation, the autoantibody level in the Con group was significantly increased by more than 18 times compared to that in the normal group (p < 0.0001) (Fig 6). Conversely, autoantibody levels in the Si group was significantly lower than that in the Con group (p = 0.0016), although it remained significantly higher than that in the Normal group (p = 0.0148). In contrast, the autoantibody levels in the ConL and SiL groups did not differ significantly from those in the Normal group. Normal mice showed the same levels as the negative controls without serum samples, with no detectable autoantibodies.

Fig 6. ELISA for detection type II collagen autoantibody.

Fig 6

The bar chart indicates mean type II collagen antibody levels in the normal (green), control (white), Si (black), ConL (red), and SiL (blue) groups. Data are expressed as the mean ± SEM of nine mice per group. ConL: control group at 40 weeks after sensitisation; SiL: Si group at 40 weeks after sensitisation. One-way ANOVA showed a significant difference among the groups (p < 0.0001), followed by Tukey’s multiple-comparison test. ****p < 0.0001 and *p < 0.05 vs. the Normal group; ††††p < 0.0001 and ††p < 0.01 vs. the Con group.

Furthermore, the amount of autoantibodies in the blood of each group, ConL and SiL groups, was also examined 40 weeks after sensitization. The autoantibody levels in both groups were significantly lower than that in the Con group (ConL, p < 0.0001; SiL, p < 0.0001), whereas no significant differences were observed between either long-term group and the Normal group. One-way ANOVA followed by Tukey’s multiple-comparison test was used for statistical analysis.

Taken together, these findings suggest that the Si-based agent was associated with a significant attenuation of the increase in type II collagen autoantibodies observed 8 weeks after sensitisation.

Discussion

In the present study, the Si-based agent showed beneficial effects on selected arthritis-related outcomes in a type II collagen-induced arthritis model. The Si group showed a lower arthritis index at week 6 and a lower incidence of bone degeneration. However, differences in severe arthritis, leg closure, and the duration of severe arthritis were not statistically significant. In addition, serum autoantibody levels were suppressed at the earlier assessment. In contrast, no significant differences in VOR or inner-ear structural outcomes were detected between the Si-based agent and control groups. These findings suggest that the beneficial effects of the Si-based agent on arthritis were not accompanied by detectable changes in the vestibular outcomes examined in this study. Further investigation is needed to clarify the mechanisms underlying RA-associated vestibular dysfunction and potential therapeutic strategies for such complications.

The main symptoms of RA, an autoimmune disease, are joint stiffness, swelling, and pain. As inflammation persists, joint structures are damaged [24]. Therefore, anti-inflammatory agents are essential in RA treatment. Methotrexate (MTX), the first-line drug for RA, promotes adenosine release, reducing inflammation [25]. NSAIDs are commonly combined with MTX [26], but long-term use raises concerns about gastrointestinal side effects [27]. Thus, safer anti-inflammatory strategies are needed.

Si-based agent exerts anti-inflammatory effects through hydrogen produced upon reaction with water [28]. Hydrogen suppresses pro-inflammatory factors such as IL-6, IL-1β, TNF-α, and ROS. We previously showed that oral Si-based agent alleviates inflammatory disease symptoms, including ulcerative colitis and interstitial pneumonia [7,8]. Furthermore, Si-based agent increases reactive sulfur species (RSS), a strong endogenous anti-inflammatory mediator [29]. These mechanisms collectively suggest strong anti-inflammatory potential. The Si-based agent alleviated inflammation in type II collagen-induced RA mouse models and significantly suppressed collagen autoantibody levels (Fig 1, 6). Because autoantibodies drive abnormal immune activation [30], their reduction is important in RA therapy. The suppression of autoantibody production may contribute to the beneficial effects of the Si-based agent on RA-related manifestations. However, the mechanism by which Si-based agent may suppress B-cell activity remains unclear. Since no side effects have been reported, Si-based agent may serve as a potentially safe therapeutic option for RA.

Our previous work showed that type II collagen-induced RA mouse models were associated with hearing loss and vestibular dysfunction [9]. Autoantibodies against type II collagen may promote CD4 ⁺ T-cell–mediated macrophage activation and cytokine production, causing tissue damage [31]. Because type II collagen is present in the inner ear, autoantibody-mediated tissue injury may contribute to vestibular dysfunction. Although Si-based agent has anti-inflammatory effects in various organs, no significant differences in VOR gain or inner-ear structural outcomes were detected between the Si and Con groups in the present study (Fig 3, 4). Comparisons with our previous findings in 19-week-old RA mice [9] also showed no clear difference in VOR gain or inner-ear morphology.

Interestingly, no further changes in the VOR-related outcomes were detected during the later stage of arthritis in the present study. In contrast, RA severity worsens over time, including joint damage and bone mineral loss [23]. This discrepancy may reflect distinct temporal patterns of arthritis-related and vestibular changes. RA severity correlates with autoantibody levels and exposure duration [32]. Although autoantibody levels were high at 8 weeks and later declined at 48 weeks (Fig 6), vestibular function did not recover, raising the possibility that vestibular dysfunction may persist after early disease development. The Si-based agent alleviated chronic RA symptoms, such as reduced joint flexibility observed in tail suspension testing, consistent with chronic RA progression.

These findings suggest that early disease-related changes may contribute to subsequent vestibular dysfunction. No immune cell infiltration was observed in the inner ear in either 19-week or long-term mice [9]. Because arthritis onset generally occurs within several weeks after the second sensitisation, early immune-mediated changes may occur during this period. Although autoantibodies are reportedly produced equally in acute and chronic stages [33], we observed long-term reductions in the Si group; however, group differences disappeared, suggesting that the suppressive effect of the Si-based agent on autoantibody levels may be limited at later stages. We hypothesize that vestibular injury may occur when autoantibody levels reach a threshold sufficient to promote inner-ear entry. Further studies correlating serum autoantibody levels with vestibular onset may provide therapeutic insights.

MRI analysis showed increased endolymphatic space area ratios in both groups compared with 19-week-old mice [9]. Tissue destruction and atrophy in the cochlear stria vascularis were observed (Fig 4), similar to findings from earlier stages. Since endolymph is produced by the stria vascularis, its degeneration may contribute to alterations in endolymphatic homeostasis. Similar long-term enlargement of the endolymphatic space has been reported in guinea pig RA models [34]. These findings suggest that long-term CIA may be associated with persistent structural changes in the inner ear, which may be relevant to vestibular dysfunction and should be considered when evaluating therapeutic interventions at later stages.

A limitation of the present study is the absence of a normal control group. Therefore, we could not determine whether vestibular dysfunction was reproduced in the present type II collagen-induced RA mouse model. In our previous study [9], VOR gain was reduced only at 2 Hz, and the magnitude of the difference was relatively small. Thus, the present vestibular findings should be interpreted cautiously. Although MRI revealed changes in the endolymphatic space in the long-term RA mouse model, the absence of a normal control group also limited our ability to determine whether these changes were specifically associated with RA. In addition, the sample size was not determined based on a formal a priori power analysis; therefore, the possibility of insufficient statistical power and a type II error cannot be excluded, particularly for the negative findings. Accordingly, the absence of statistically significant differences between the Si and Con groups should be interpreted as a lack of detectable differences under the conditions of the present study, rather than evidence that the Si-based agent has no effect on vestibular or inner-ear outcomes. Further studies with an appropriate normal control group, adequately determined sample sizes, and longitudinal assessments are warranted to clarify the relationship between RA, vestibular dysfunction, and changes in the inner ear.

In summary, the present findings suggest that the therapeutic effects of the Si-based agent may differ according to the pathological manifestations of RA. The beneficial effects observed on arthritis-related outcomes may have implications for the development of therapeutic approaches aimed at improving quality of life, while the mechanisms underlying RA-associated vestibular dysfunction and inner-ear structural changes remain to be elucidated. Further studies are warranted to clarify these mechanisms and explore therapeutic strategies for vestibular complications of RA.

Supporting information

S1 Table. The Excel files labeled “Arthritis Index,” each containing raw data for individual mice regarding the arthritis index.

(XLSX)

pone.0361954.s001.xlsx (5.8KB, xlsx)
S2 Table. The Excel files labeled “edema rate,” each containing raw data for individual mice regarding the edema rate.

(XLSX)

pone.0361954.s002.xlsx (10.2KB, xlsx)
S3 Table. The Excel files labeled “Autoantibody levels,” each containing raw data for individual mice regarding the autoantibody levels.

(XLSX)

pone.0361954.s003.xlsx (9.4KB, xlsx)
S4 Table. The Excel files labeled “VOR,” each containing raw data for individual mice regarding the VOR.

(XLSX)

pone.0361954.s004.xlsx (3.9KB, xlsx)
S5 Table. Author checklist of ARRIVE Guideline.

(PDF)

pone.0361954.s005.pdf (176.3KB, pdf)

Acknowledgments

We thank Ms. M. Hasegawa for technical assistance. We would like to thank Editage (www.editage.com) for English language editing and the Center for Medical Research and Education, Graduate School for Medicine, Osaka University, for technical support.

Data Availability

All relevant data generated or analyzed during this study are included in this published article.

Funding Statement

This work was supported by the Center of Innovation Program (COI Program, Grant Number JPMJCE1310, JST, Japan) and JSPS KAKENHI (Grant Number 23K15862). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38. doi: 10.1016/S0140-6736(16)30173-8 [DOI] [PubMed] [Google Scholar]
  • 2.Yilmaz S, Erbek S, Erbek SS, Ozgirgin N, Yucel E. Abnormal electronystagmography in rheumatoid arthritis. Auris Nasus Larynx. 2007;34(3):307–11. doi: 10.1016/j.anl.2006.11.003 [DOI] [PubMed] [Google Scholar]
  • 3.Heydari N, Hajiabolhassani F, Fatahi J, Movaseghi S, Jalaie S. Vestibular evoked myogenic potentials in patients with rheumatoid arthritis. Med J Islam Repub Iran. 2015;29:216. [PMC free article] [PubMed] [Google Scholar]
  • 4.Kent AE, Gürses E, Karabekiroğlu F, Genç A. Balance impairment in patients with rheumatoid arthritis and ankylosing spondylitis. Curr Rheumatol Rev. 2023;:10.2174/1573397119666230828162611. doi: 10.2174/1573397119666230828162611 [DOI] [PubMed] [Google Scholar]
  • 5.Kobayashi Y, Matsuda S, Imamura K, Kobayashi H. Hydrogen generation by reaction of Si nanopowder with neutral water. J Nanopart Res. 2017;19(5):176. doi: 10.1007/s11051-017-3873-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kikkawa YS, Nakagawa T, Taniguchi M, Ito J. Hydrogen protects auditory hair cells from cisplatin-induced free radicals. Neurosci Lett. 2014;579:125–9. doi: 10.1016/j.neulet.2014.07.025 [DOI] [PubMed] [Google Scholar]
  • 7.Koyama Y, Kobayashi Y, Hirota I, Sun Y, Ohtsu I, Imai H, et al. A new therapy against ulcerative colitis via the intestine and brain using the Si-based agent. Sci Rep. 2022;12(1):9634. doi: 10.1038/s41598-022-13655-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Shimada M, Koyama Y, Kobayashi Y, Kobayashi H, Shimada S. Effect of the new silicon-based agent on the symptoms of interstitial pneumonitis. Sci Rep. 2023;13(1):5707. doi: 10.1038/s41598-023-32745-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Harada S, Koyama Y, Imai T, Yoshioka Y, Sumi T, Inohara H, et al. A mouse model of autoimmune inner ear disease without endolymphatic hydrops. Biochim Biophys Acta Mol Basis Dis. 2024;1870(5):167198. doi: 10.1016/j.bbadis.2024.167198 [DOI] [PubMed] [Google Scholar]
  • 10.Kobayashi Y, Imamura R, Koyama Y, Kondo M, Kobayashi H, Nonomura N, et al. Renoprotective and neuroprotective effects of enteric hydrogen generation from Si-based agent. Sci Rep. 2020;10(1):5859. doi: 10.1038/s41598-020-62755-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wood FD, Pearson CM, Tanaka A. Capacity of mycobacterial wax D and its subfractions to induce adjuvant arthritis in rats. Int Arch Allergy Appl Immunol. 1969;35(5):456–67. doi: 10.1159/000230198 [DOI] [PubMed] [Google Scholar]
  • 12.Rinaldi S, Brennan KM, Willison HJ. Heteromeric glycolipid complexes as modulators of autoantibody and lectin binding. Prog Lipid Res. 2010;49(1):87–95. doi: 10.1016/j.plipres.2009.09.001 [DOI] [PubMed] [Google Scholar]
  • 13.Imai T, Takimoto Y, Takeda N, Uno A, Inohara H, Shimada S. High-speed video-oculography for measuring three-dimensional rotation vectors of eye movements in mice. PLoS One. 2016;11(3):e0152307. doi: 10.1371/journal.pone.0152307 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Calabrese DR, Hullar TE. Planar relationships of the semicircular canals in two strains of mice. J Assoc Res Otolaryngol. 2006;7(2):151–9. doi: 10.1007/s10162-006-0031-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Takimoto Y, Imai T, Kondo M, Hanada Y, Uno A, Ishida Y, et al. Cisplatin-induced toxicity decreases the mouse vestibulo-ocular reflex. Toxicol Lett. 2016;262:49–54. doi: 10.1016/j.toxlet.2016.09.009 [DOI] [PubMed] [Google Scholar]
  • 16.Haslwanter T. Mathematics of three-dimensional eye rotations. Vision Res. 1995;35(12):1727–39. doi: 10.1016/0042-6989(94)00257-m [DOI] [PubMed] [Google Scholar]
  • 17.Arzi M, Magnin M. A fuzzy set theoretical approach to automatic analysis of nystagmic eye movements. IEEE Trans Biomed Eng. 1989;36(9):954–63. doi: 10.1109/10.35304 [DOI] [PubMed] [Google Scholar]
  • 18.Naoi K. Three-dimensional eye movement simulator extracting instantaneous eye movement rotation axes, the plane formed by rotation axes, and innervations for eye muscles. IEICE Transactions on Information and Systems. 2003;86(11). [Google Scholar]
  • 19.Kawai S, Takagi Y, Kaneko S, Kurosawa T. Effect of three types of mixed anesthetic agents alternate to ketamine in mice. Exp Anim. 2011;60(5):481–7. doi: 10.1538/expanim.60.481 [DOI] [PubMed] [Google Scholar]
  • 20.Counter SA, Bjelke B, Borg E, Klason T, Chen Z, Duan ML. Magnetic resonance imaging of the membranous labyrinth during in vivo gadolinium (Gd-DTPA-BMA) uptake in the normal and lesioned cochlea. Neuroreport. 2000;11(18):3979–83. doi: 10.1097/00001756-200012180-00015 [DOI] [PubMed] [Google Scholar]
  • 21.Hennig J, Nauerth A, Friedburg H. RARE imaging: A fast imaging method for clinical MR. Magn Reson Med. 1986;3(6):823–33. doi: 10.1002/mrm.1910030602 [DOI] [PubMed] [Google Scholar]
  • 22.Imai T, Nishiike S, Oshima K, Tanaka H, Tsuruta Y, Tomiyama Y. The resected area of the posterior wall of the external auditory canal during transcanal endoscopic ear surgery for cholesteatoma. Auris Nasus Larynx. 2017;44(2):141–6. doi: 10.1016/j.anl.2016.06.003 [DOI] [PubMed] [Google Scholar]
  • 23.Schuh BM, Macáková K, Feješ A, Groß T, Belvončíková P, Janko J, et al. Sex differences in long-term effects of collagen-induced arthritis in middle-aged mice. Front Physiol. 2023;14:1195604. doi: 10.3389/fphys.2023.1195604 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Kucharska-Lusina A. Individual and molecular risk factors for the development of rheumatoid arthritis. Wiad Lek. 2024;77(10):2057–69. doi: 10.36740/WLek/193976 [DOI] [PubMed] [Google Scholar]
  • 25.Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: Treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford). 2005;44(1):61–6. doi: 10.1093/rheumatology/keh512 [DOI] [PubMed] [Google Scholar]
  • 26.Segre EJ. Naproxen sodium (Anaprox): Pharmacology, pharmacokinetics and drug interactions. J Reprod Med. 1980;25(4 Suppl):222–5. [PubMed] [Google Scholar]
  • 27.Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology. 2018;154(3):500–14. doi: 10.1053/j.gastro.2017.10.049 [DOI] [PubMed] [Google Scholar]
  • 28.Koyama Y, Kobayashi Y, Kobayashi H, Shimada S. Diverse possibilities of si-based agent, a unique new antioxidant. Antioxidants (Basel). 2023;12(5):1061. doi: 10.3390/antiox12051061 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Zhang T, Ono K, Tsutsuki H, Ihara H, Islam W, Akaike T, et al. Enhanced cellular polysulfides negatively regulate TLR4 signaling and mitigate lethal endotoxin shock. Cell Chem Biol. 2019;26(5):686-698.e4. doi: 10.1016/j.chembiol.2019.02.003 [DOI] [PubMed] [Google Scholar]
  • 30.Plebani M, Pittoni M, Celadin M, Bernardi D, Mion MM. Recent advances in diagnostic technologies for autoimmune diseases. Autoimmun Rev. 2009;8(3):238–43. doi: 10.1016/j.autrev.2008.07.032 [DOI] [PubMed] [Google Scholar]
  • 31.Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–61. doi: 10.1038/nature01661 [DOI] [PubMed] [Google Scholar]
  • 32.Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM. Induction of arthritis with monoclonal antibodies to collagen. J Immunol. 1992;148(7):2103–8. doi: 10.4049/jimmunol.148.7.2103 [DOI] [PubMed] [Google Scholar]
  • 33.Kresina TF, Finegan CK. Restricted expression of anti-type II collagen antibody isotypes in mice suppressed for collagen-induced arthritis. Ann Rheum Dis. 1986;45(1):60–6. doi: 10.1136/ard.45.1.60 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Yoo TJ, Yazawa Y, Tomoda K, Floyd R. Type II collagen-induced autoimmune endolymphatic hydrops in guinea pig. Science. 1983;222(4619):65–7. doi: 10.1126/science.6623056 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Toru Miwa

11 Sep 2026

Dear Dr. Koyama,

Thank you for submitting your manuscript to PLOS One. After careful consideration, we feel that it has merit but does not fully meet PLOS One’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 10 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS One offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Toru Miwa

Academic Editor

PLOS One

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“This work was supported by the Center of Innovation Program (COI Program, Grant Number JPMJCE1310, JST, Japan) and JSPS KAKENHI (Grant Number 23K15862).”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This research was supported by the Center of Innovation Program (COI Program, Grant Number JPMJCE1310, JST Japan, and JSPS KAKENHI (No. 23K15862). We thank Ms. M.  Hasegawa for technical assistance. We would like to thank Editage (www.editage.com) for English language editing and the Center for Medical Research and Education, Graduate School for Medicine, Osaka University, for technical support ”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This work was supported by the Center of Innovation Program (COI Program, Grant Number JPMJCE1310, JST, Japan) and JSPS KAKENHI (Grant Number 23K15862).”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

[Note: HTML markup is below. Please do not edit.]

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

**********

Reviewer #1: This study investigated the effects of a Si-based agent on arthritis and vestibular dysfunction using a type II collagen-induced arthritis (CIA) mouse model. This work extends the authors’ previous study (Ref. 9). The authors evaluated arthritis severity, VOR, histological findings, endolymphatic hydrops by MRI, and serum type II collagen antibody levels.

However, there are several important concerns regarding the study design, statistical analysis, and interpretation of the results that weaken the main conclusion that the Si-based agent improves arthritis but has no effect on vestibular dysfunction. In addition, the Methods section contains missing information, unnecessary overlap with the previous publication, and inconsistencies with the presented results. Addressing these issues would substantially strengthen the manuscript.

Major comments

1. The most important limitation of this study is the lack of a normal control group. Only untreated and treated CIA mice were compared. Therefore, it is impossible to confirm whether vestibular dysfunction was actually reproduced in the present experiment. In the previous study (Ref. 9), VOR gain was reduced only at 2 Hz, and the difference was relatively small. This important limitation should be discussed more carefully. Based on the present data, it is appropriate to conclude only that no significant difference was detected between the two CIA groups, rather than concluding that the Si-based agent is ineffective for vestibular dysfunction.

2. In the previous study, both VOR and static tilt analyses were performed, and static tilt appeared to detect vestibular dysfunction more clearly. In the present study, only VOR was evaluated, but the reason for excluding static tilt analysis is not explained. In addition, VOR mainly reflects lateral semicircular canal function. Therefore, the conclusion should not be generalized to overall vestibular function. Please explain why only VOR was selected.

3. The description of the statistical analysis is insufficient. The Methods section states that Student’s t-test or Mann-Whitney U test was used; however, it is unclear which statistical test was applied to each analysis. Please specify the statistical method used for each figure or dataset. In addition, Figure 6 includes three groups (Normal, CIA, and CIA+Si), but the statistical method used for this comparison is not described. Furthermore, the manuscript states that a paired t-test was used for comparison with the Normal group. If these groups consisted of independent animals, a paired t-test would not be appropriate. Please clarify whether this is a description error or the actual statistical method used. The statistical analysis should be described in sufficient detail to allow readers to assess the appropriateness and reproducibility of the analyses.

4. The main conclusion of this study is based on negative results (no significant differences in VOR, histology, or MRI). However, no information is provided regarding sample size justification or statistical power. Therefore, it is difficult to determine whether there is truly no treatment effect or whether the study is underpowered (Type II error). Since the main conclusion relies on negative findings, this point should be discussed. In addition, the present data indicate that no significant difference was detected; they do not prove that the treatment has no effect. The interpretation of the negative findings should therefore be more cautious throughout the Discussion.

5. Arthritis scoring is subjective and susceptible to observer bias. The manuscript does not describe whether the assessment was performed in a blinded manner or how many evaluators were involved. Please provide these methodological details.

6. MRI was used to evaluate endolymphatic hydrops. However, the previous study did not demonstrate obvious hydrops in the CIA model. Since no normal control group was included in the present study, the rationale for including MRI as a major outcome measure should be explained more clearly in the Introduction or Discussion.

Minor comments

1. Figure 6 presents ELISA data for serum type II collagen antibody levels, but no ELISA method is described in the Methods section. Please add the experimental details, including the assay kit, procedures, and analysis. In addition, normal mice are included in Figure 6, but the Methods section does not describe these animals. Please clarify how the normal controls were prepared and analyzed.

2. The description of the VOR experiment in the Methods section is largely identical to that in the previous publication. I suggest citing the previous paper and describing only the information necessary for the present study.

3. The section entitled “Eye movement recording” (around Line 171) appears to describe the static tilt experiment. However, no static tilt results are presented in this manuscript. If this section is not relevant, it should be removed.

4. The Abstract is unbalanced. Most of the Abstract is devoted to the Background, whereas the Methods and Results are too brief. The study design, evaluation methods, and main findings should be described more clearly. A structured Abstract (or a similar format) would improve readability. The major negative findings should also be clearly stated.

Overall, this study addresses an interesting topic, and the finding that the Si-based agent improved arthritis in the CIA model is valuable. However, several important limitations in the study design, statistical analysis, and interpretation of the negative findings should be addressed before the conclusions can be fully supported. In particular, the conclusions regarding vestibular dysfunction should be limited to what is supported by the present data. Revision of the Methods and Discussion would substantially improve the manuscript.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Nov 6;21(11):e0361954. doi: 10.1371/journal.pone.0361954.r002

Author response to Decision Letter 1


21 Sep 2026

Editor

Thank you for submitting your manuscript to PLOS One. After careful consideration, we feel that it has merit but does not fully meet PLOS One’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Response

We sincerely thank the Editor for the careful consideration of our manuscript and for the constructive comments. We have carefully addressed all of the points raised and revised the manuscript accordingly. We hope that the revised manuscript will now meet the publication criteria of PLOS ONE.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response

Thank you for your comment. We have carefully reviewed the manuscript according to the PLOS ONE style requirements and revised the manuscript formatting and file names accordingly, following the provided PLOS ONE style templates.

2. Thank you for stating the following financial disclosure:

“This work was supported by the Center of Innovation Program (COI Program, Grant Number JPMJCE1310, JST, Japan) and JSPS KAKENHI (Grant Number 23K15862).”

Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Response

Thank you for your comment. We have revised the “Funding” section of the manuscript (lines 435-437 on page 19) to include the following Role of Funder statement and have also included this statement in the cover letter:

“The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This research was supported by the Center of Innovation Program (COI Program, Grant Number JPMJCE1310, JST Japan, and JSPS KAKENHI (No. 23K15862). We thank Ms. M. Hasegawa for technical assistance. We would like to thank Editage (www.editage.com) for English language editing and the Center for Medical Research and Education, Graduate School for Medicine, Osaka University, for technical support ”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This work was supported by the Center of Innovation Program (COI Program, Grant Number JPMJCE1310, JST, Japan) and JSPS KAKENHI (Grant Number 23K15862).”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response

Thank you for your comment. We have removed all funding-related information from the “Acknowledgments” section of the manuscript, as requested.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Response

Thank you for your comment. We have moved the ethics statement from the “Declarations” section to the beginning of the “Materials and Methods” section, as requested.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response

Thank you for your comment. This manuscript does not contain any Supporting Information files.

6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Response

Thank you for the clarification. No specific publications were recommended for citation in the reviewer comments.

Reviewer #1

This study investigated the effects of a Si-based agent on arthritis and vestibular dysfunction using a type II collagen-induced arthritis (CIA) mouse model. This work extends the authors’ previous study (Ref. 9). The authors evaluated arthritis severity, VOR, histological findings, endolymphatic hydrops by MRI, and serum type II collagen antibody levels.

However, there are several important concerns regarding the study design, statistical analysis, and interpretation of the results that weaken the main conclusion that the Si-based agent improves arthritis but has no effect on vestibular dysfunction. In addition, the Methods section contains missing information, unnecessary overlap with the previous publication, and inconsistencies with the presented results. Addressing these issues would substantially strengthen the manuscript.

Response

Thank you for the careful and constructive evaluation of our manuscript. We have carefully addressed all of the concerns regarding the study design, statistical analysis, interpretation, Methods, and consistency with our previous publication. The manuscript has been revised accordingly to clarify and strengthen the presentation of our findings and conclusions.

Major comments

1. The most important limitation of this study is the lack of a normal control group. Only untreated and treated CIA mice were compared. Therefore, it is impossible to confirm whether vestibular dysfunction was actually reproduced in the present experiment. In the previous study (Ref. 9), VOR gain was reduced only at 2 Hz, and the difference was relatively small. This important limitation should be discussed more carefully. Based on the present data, it is appropriate to conclude only that no significant difference was detected between the two CIA groups, rather than concluding that the Si-based agent is ineffective for vestibular dysfunction.

Response 1

Thank you for this important comment. We agree that the absence of a normal control group limits our ability to determine whether vestibular dysfunction was reproduced in the present CIA model. We have added this limitation to the “Discussion” section (lines 399-413 on pages 17-18), and noted that, in our previous study [Ref No. 9 in the text], the reduction in VOR gain was limited to 2 Hz and relatively small.

Accordingly, we have revised the interpretation of the vestibular findings throughout the manuscript and now state that no significant differences in vestibular function-related outcomes were detected between the Si-based agent and control groups, rather than concluding that the Si-based agent was ineffective against vestibular dysfunction.

We have also revised the “Abstract” and “Discussion” section to ensure that the conclusions are appropriately limited to the present data.

2. In the previous study, both VOR and static tilt analyses were performed, and static tilt appeared to detect vestibular dysfunction more clearly. In the present study, only VOR was evaluated, but the reason for excluding static tilt analysis is not explained. In addition, VOR mainly reflects lateral semicircular canal function. Therefore, the conclusion should not be generalized to overall vestibular function. Please explain why only VOR was selected.

Response 2

Thank you for this important comment. In our previous study [Ref No. 9 in the text], both VOR and static tilt analyses were performed. The static tilt analysis, which evaluates otolith function, showed no significant difference between the normal and RA groups, whereas the VOR analysis detected a significant difference, indicating that semicircular canal dysfunction was more evident in the RA model. Therefore, we selected VOR testing as the vestibular assessment in the present study.

We agree that VOR primarily reflects lateral semicircular canal function and that the present findings should not be generalized to overall vestibular function. We have clarified the rationale for selecting VOR in the “Vestibulo-ocular reflex test” subsection of the “Materials and Methods” section (lines 137-138 on page 7) and have revised the “Results” (lines 264-266 on page 12) “Discussion” section (lines 331-339 on page 15, lines 365-373, 375-376 on pages 16, lines 379-380 on page 17) to acknowledge this limitation and to appropriately restrict the interpretation of our findings to the vestibular function assessed by VOR.

3. The description of the statistical analysis is insufficient. The Methods section states that Student’s t-test or Mann-Whitney U test was used; however, it is unclear which statistical test was applied to each analysis. Please specify the statistical method used for each figure or dataset. In addition, Figure 6 includes three groups (Normal, CIA, and CIA+Si), but the statistical method used for this comparison is not described. Furthermore, the manuscript states that a paired t-test was used for comparison with the Normal group. If these groups consisted of independent animals, a paired t-test would not be appropriate. Please clarify whether this is a description error or the actual statistical method used. The statistical analysis should be described in sufficient detail to allow readers to assess the appropriateness and reproducibility of the analyses.

Response 3

Thank you for this important comment. We agree that the statistical methods should be described in sufficient detail for each analysis to ensure appropriate interpretation and reproducibility.

We carefully rechecked the statistical analyses and revised the “Statistical Analysis” subsection of the “Materials and Methods” section (lines 210-221 on page 10) accordingly. The arthritis index and hindlimb oedema rate were analysed using linear mixed-effects models, followed by Student’s t-tests for between-group comparisons when a significant group × week interaction was detected. Bone degeneration, arthritis severity, duration of inflammation, and leg closure rate were analyzed using unpaired Student’s t-tests. VOR data were analyzed using a two-way mixed-effects model, the MRI-derived endolymphatic space area ratio using the Mann–Whitney U test, and serum type II collagen-specific autoantibody levels using one-way analysis of variance followed by Tukey’s multiple-comparison test.

Regarding Figure 6, the Normal, Con, Si, ConL, and SiL groups consisted of independent animals. Therefore, the description of a paired t-test in the previous version was incorrect and represented a description error in the Methods section. The data were analysed using one-way analysis of variance followed by Tukey’s multiple-comparison test. We have corrected this error in the revised manuscript.

These revisions clarify the statistical methods used for each dataset. We also revised the corresponding “Results” sections (lines 229-235, 247-249 on page 11, lines 271-277 on pages 12-13, lines 314-317, 321-328 on pages 14-15) and Figure legends (Fig.1a, 1f, 3b and 6) to reflect the revised statistical analyses and their results.

4. The main conclusion of this study is based on negative results (no significant differences in VOR, histology, or MRI). However, no information is provided regarding sample size justification or statistical power. Therefore, it is difficult to determine whether there is truly no treatment effect or whether the study is underpowered (Type II error). Since the main conclusion relies on negative findings, this point should be discussed. In addition, the present data indicate that no significant difference was detected; they do not prove that the treatment has no effect. The interpretation of the negative findings should therefore be more cautious throughout the Discussion.

Response 4

Thank you for this important comment. We agree that the absence of statistically significant differences does not establish the absence of a treatment effect and that insufficient statistical power should be considered when interpreting negative findings. A formal a priori power analysis was not performed in the present study. We have therefore added this point as a limitation in the “Discussion” section (lines 399-413 on pages 17-18) and revised the interpretation of the negative findings throughout the manuscript.

Specifically, we now clarify that the absence of statistically significant differences indicates that no detectable differences were observed under the conditions of the present study, rather than demonstrating that the Si-based agent has no effect. We have also revised the wording in the Discussion to avoid overinterpretation of the VOR, MRI, and histological findings.

5. Arthritis scoring is subjective and susceptible to observer bias. The manuscript does not describe whether the assessment was performed in a blinded manner or how many evaluators were involved. Please provide these methodological details.

Response 5

Thank you for this important comment. The type II collagen-induced arthritis model was established by Japan SLC, using a well-established and widely used protocol. Arthritis scoring was performed by an evaluator who was independent of the personnel responsible for the treatment and was unaware of the group assignments and individual treatment information. We have added these methodological details to the “Animals and model preparation” subsection of the “Materials and Methods” section (lines 105-106, 120-123 on pages 5-6).

6. MRI was used to evaluate endolymphatic hydrops. However, the previous study did not demonstrate obvious hydrops in the CIA model. Since no normal control group was included in the present study, the rationale for including MRI as a major outcome measure should be explained more clearly in the Introduction or Discussion.

Response 6

Thank you for this important comment. As noted by the reviewer, our previous study [Ref No. 9 in the text] did not demonstrate obvious endolymphatic hydrops when CIA mice were compared with WT mice. Therefore, we agree that the rationale for evaluating MRI as a measure of endolymphatic hydrops in the present study was limited.

In the present study, our purpose was to examine whether long-term administration of the Si-based agent altered the endolymphatic space in CIA mice, rather than to specifically evaluate endolymphatic hydrops. We have therefore revised the description of the MRI assessment to focus on changes in the endolymphatic space and clarified this rationale in the “Discussion” section (lines 377-381, 387-389, 399 on page 17). We also revised the interpretation of the MRI methods and findings accordingly (lines 191-197 on page 9, lines 294, 297-298 on page 13, 304-307 on page 14).

Minor comments

1. Figure 6 presents ELISA data for serum type II collagen antibody levels, but no ELISA method is described in the Methods section. Please add the experimental details, including the assay kit, procedures, and analysis. In addition, normal mice are included in Figure 6, but the Methods section does not describe these animals. Please clarify how the normal controls were prepared and analyzed.

Response 1

Thank you for this important comment. We have added the detailed ELISA procedure for measuring serum type II collagen antibody levels to the “Materials and Methods” section (lines 199-207 on pages 9-10), including the assay kit, experimental procedure, and data analysis. We have also clarified the preparation and analysis of the normal control mice shown in Figure 6 and added the relevant information to the “Animals and model preparation” subsection of “Materials and Methods” section (lines 102-104 on page 6).

2. The description of the VOR experiment in the Methods section is largely identical to that in the previous publication. I suggest citing the previous paper and describing only the information necessary for the present study.

Response 2

Thank you for this helpful comment. We have revised the VOR experiment section of the “Materials and Methods” section (lines 132-156 on pages 7-8) to avoid unnecessary duplication with our previous publication. We now cite the previous paper [Ref No. 9 in the text] and provide only the methodological details necessary for the present study.

3. The section entitled “Eye movement recording” (around Line 171) appears to describe the static tilt experiment. However, no static tilt results are presented in this manuscript. If this section is not relevant, it should be removed.

Response 3

Thank you for pointing this out. We completely overlooked the inclusion of this section during manuscript preparation. We agree that the “Eye movement recording” subsection describes the static tilt experiment, which was not performed or reported in the present study. We have therefore removed this section from the “Materials and Methods” section.

4. The Abstract is unbalanced. Most of the Abstract is devoted to the Background, whereas the Methods and Results are too brief. The study design, evaluation methods, and main findings should be described more clearly. A structured Abstract (or a similar format) would improve readability. The major negative findings should also be clearly stated.

Response 4

Thank you for this helpful comment. We have substantially revised the “Abstract” section to improve its balance and readability. The Background has been shortened, while the study design, evaluation methods, and main findings have been described more clearly. We have also explicitly stated the major negative findings regarding vestibular function-related outcomes.

Overall, this study addresses an interesting topic, and the finding that the Si-based agent improved arthritis in the CIA model is valuable. However, several important limitations in the study design, statistical analysis, and interpretation of the negative findings should be addressed before the conclusions can be fully supported. In particular, the conclusions regarding vestibular dysfunction should be limited to what is supported by the present data. Revision of the Methods and Discussion would substantially improve the manuscript.

Response

Thank you for the valuable and constructive comments. We have carefully addressed the concerns regarding the study design, statistical analysis, and interpretation of the findings, and revised the Methods and Discussion accordingly. We have also appropriately limited our conclusions regarding vestibular dysfunction to what is supported by the present data.

Attachment

Submitted filename: Response_to_ Reviewers .docx

pone.0361954.s007.docx (25.6KB, docx)

Decision Letter 1

Toru Miwa

12 Oct 2026

Dear Dr. Koyama,

Thank you for submitting your manuscript to PLOS One. After careful consideration, we feel that it has merit but does not fully meet PLOS One’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 11 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS One offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Toru Miwa

Academic Editor

PLOS One

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

**********

Reviewer #1: The authors have adequately addressed most of my previous comments, and the manuscript has improved substantially. However, a few issues remain.

Major comments

1. Multiple comparisons (Fig. 1a)

The use of a linear mixed-effects model is an improvement. However, the subsequent Student's t-tests at individual time points were performed without adjustment for multiple comparisons. I suggest omitting these post hoc comparisons and focusing on the significant group × week interaction. Alternatively, an appropriate multiple-comparison adjustment should be applied.

2. Statistical analysis of arthritis-related outcomes (Figs. 1 and 2)

The Methods section states that unpaired Student's t-tests were used for bone degeneration, arthritis severity, duration of inflammation, and leg closure rate, but the corresponding p-values are not clearly reported. Since bone degeneration, arthritis severity, and leg closure rate are binary outcomes, Fisher's exact test would be more appropriate, particularly given the small sample size (n = 9 per group). Please revise the analyses accordingly and report the results. Even if some comparisons are not statistically significant, the observed differences between groups should be described and interpreted cautiously.

3. Interpretation of the findings

Although the Discussion has been revised appropriately, some statements in the Results remain overly definitive. For example, the heading at lines 279–280 and the concluding statement at lines 291–293 imply that the Si-based agent was ineffective. However, the absence of detectable differences does not establish the absence of a treatment effect. Furthermore, the qualitative histological findings do not directly support conclusions about vestibular function. Please revise these statements and ensure consistent interpretation throughout the manuscript.

Minor comments

1. Line 248: “Fig. 1g” should be corrected to “Fig. 1f”.

2. Lines 569–572: The descriptions of Figures 1b and 1c appear to be reversed. Please correct the figure legends.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Nov 6;21(11):e0361954. doi: 10.1371/journal.pone.0361954.r004

Author response to Decision Letter 2


18 Oct 2026

Editor’s comment

Thank you for submitting your manuscript to PLOS One. After careful consideration, we feel that it has merit but does not fully meet PLOS One’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Response

Thank you for the opportunity to revise our manuscript. We have carefully addressed the reviewers’ comments and revised the manuscript accordingly.

Reviewer #1: The authors have adequately addressed most of my previous comments, and the manuscript has improved substantially. However, a few issues remain.

Response

Thank you for your positive assessment of our revised manuscript. We have carefully addressed the remaining comments and revised the manuscript accordingly.

Major comments

1. Multiple comparisons (Fig. 1a)

The use of a linear mixed-effects model is an improvement. However, the subsequent Student's t-tests at individual time points were performed without adjustment for multiple comparisons. I suggest omitting these post hoc comparisons and focusing on the significant group × week interaction. Alternatively, an appropriate multiple-comparison adjustment should be applied.

Response 1

Thank you for this important comment. The between-group comparisons at individual time points were performed based on the significant group × week interaction, with adjustment for multiple comparisons. We have clarified the statistical procedure in both the “Results” section (lines 239-240 on page 14) and the corresponding Fig1a legend to ensure consistency in the presentation of the findings.

2. Statistical analysis of arthritis-related outcomes (Figs. 1 and 2)

The Methods section states that unpaired Student's t-tests were used for bone degeneration, arthritis severity, duration of inflammation, and leg closure rate, but the corresponding p-values are not clearly reported. Since bone degeneration, arthritis severity, and leg closure rate are binary outcomes, Fisher's exact test would be more appropriate, particularly given the small sample size (n = 9 per group). Please revise the analyses accordingly and report the results. Even if some comparisons are not statistically significant, the observed differences between groups should be described and interpreted cautiously.

Response 2

Thank you for this valuable suggestion. We agree that Fisher’s exact test is more appropriate than the unpaired Student’s t-test for comparing binary outcomes, particularly given the small sample size. Accordingly, we reanalyzed bone degeneration, arthritis severity, and arthritis-related leg closure using Fisher’s exact test. The incidence of bone degeneration was significantly lower in the Si group than in the Con group (77.8% vs. 11.1%, p = 0.0152). In contrast, the differences in the proportion of mice with severe arthritis (77.8% vs. 55.6%, p = 0.6199) and arthritis-related leg closure (77.8% vs. 22.2%, p = 0.0567) were not statistically significant. The duration of severe arthritis, defined as the number of weeks during which the arthritis index was ≥4, was compared using the Wilcoxon rank-sum test. Although this duration was numerically shorter in the Si group, the difference was not statistically significant (p = 0.0753).

We have revised the “Statistical Analysis” subsection of the “Materials & Methods” (lines 212, 216-220 on page 13) and “Results” (lines 243-254 on page 15, 261-262, lines 270-273 on page 16), “Discussion” section (lines 341-345 on page 20), and Fig.1,2 legends to reflect the updated statistical analyses and results. We have also revised the interpretation to distinguish statistically significant findings from numerical differences that did not reach statistical significance.

3. Interpretation of the findings

Although the Discussion has been revised appropriately, some statements in the Results remain overly definitive. For example, the heading at lines 279–280 and the concluding statement at lines 291–293 imply that the Si-based agent was ineffective. However, the absence of detectable differences does not establish the absence of a treatment effect. Furthermore, the qualitative histological findings do not directly support conclusions about vestibular function. Please revise these statements and ensure consistent interpretation throughout the manuscript.

Response 3

Thank you for this valuable comment. We have revised the Results section to avoid overly definitive statements regarding the effects of the Si-based agent. Specifically, we have revised the relevant headings and concluding statements to clarify that the absence of statistically significant differences does not establish the absence of a treatment effect. We have also revised the description of the histological findings to limit the conclusions to the observed structural changes, without inferring effects on vestibular function. These revisions have been made consistently throughout the “Results” section (line 276 on page 16, lines 290-293 on page 17, lines 301-302, 307-309, 316-317 on page 18).

Minor comments

1. Line 248: “Fig. 1g” should be corrected to “Fig. 1f”.

Response 1

Thank you for pointing this out. We have corrected “Fig. 1g” to “Fig. 1f” in Line 257 of the revised manuscript.

2. Lines 569–572: The descriptions of Figures 1b and 1c appear to be reversed. Please correct the figure legends.

Response 2

Thank you for pointing this out. We have revised the figure legends to clarify that Fig. 1b shows the proportion of mice with an arthritis index of 4 or higher (arthritis severity), whereas Fig. 1c shows the proportion of mice with bone degeneration (arthritis index = 5). Because the Results section describes arthritis severity followed by bone degeneration, we have also switched the descriptions of Fig. 1b and Fig. 1c in the Figure legends to maintain consistency with the order of presentation in the “Results” section. The Figure legends have been corrected accordingly.

Attachment

Submitted filename: Response to Reviewrers.docx

pone.0361954.s008.docx (19.2KB, docx)

Decision Letter 2

Toru Miwa

20 Oct 2026

Evaluation of the Efficacy of Si-based Agent in Rheumatoid Arthritis with Complicating vestibular impairment

PONE-D-26-31345R2

Dear Dr. Koyama,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Toru Miwa

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: (No Response)

**********

Reviewer #1: The authors have adequately addressed my previous concerns, and the manuscript has improved substantially.

I have only one minor comment regarding the statistical analysis. Although the authors state that multiple-comparison adjustment was applied to the post hoc comparisons in Fig. 1a, the specific adjustment method is not described. Please specify the method used in the Statistical Analysis section to ensure reproducibility.

Otherwise, I have no further concerns and consider the manuscript suitable for publication.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

**********

Acceptance letter

Toru Miwa

PONE-D-26-31345R2

PLOS One

Dear Dr. Koyama,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS One and supporting open access.

Kind regards,

PLOS One Editorial Office Staff

on behalf of

Dr. Toru Miwa

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. The Excel files labeled “Arthritis Index,” each containing raw data for individual mice regarding the arthritis index.

    (XLSX)

    pone.0361954.s001.xlsx (5.8KB, xlsx)
    S2 Table. The Excel files labeled “edema rate,” each containing raw data for individual mice regarding the edema rate.

    (XLSX)

    pone.0361954.s002.xlsx (10.2KB, xlsx)
    S3 Table. The Excel files labeled “Autoantibody levels,” each containing raw data for individual mice regarding the autoantibody levels.

    (XLSX)

    pone.0361954.s003.xlsx (9.4KB, xlsx)
    S4 Table. The Excel files labeled “VOR,” each containing raw data for individual mice regarding the VOR.

    (XLSX)

    pone.0361954.s004.xlsx (3.9KB, xlsx)
    S5 Table. Author checklist of ARRIVE Guideline.

    (PDF)

    pone.0361954.s005.pdf (176.3KB, pdf)
    Attachment

    Submitted filename: Response_to_ Reviewers .docx

    pone.0361954.s007.docx (25.6KB, docx)
    Attachment

    Submitted filename: Response to Reviewrers.docx

    pone.0361954.s008.docx (19.2KB, docx)

    Data Availability Statement

    All relevant data generated or analyzed during this study are included in this published article.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES